ARA 290

ARA-290 (Cibinetide, pHBSP)

CAS: 1208243-50-8

Aliases: Cibinetide, Pyroglutamate Helix B Surface Peptide

⚠️ For laboratory research use only; not a marketed drug

Basic Information

– Amino acid sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (11-peptide, N-terminal pyroglutamate cyclization)

– Molecular formula: \(\mathbf{C_{51}H_{84}N_{16}O_{21}}\)

– Molecular weight: 1257.3 Da

– Target: IRR (heterodimer of the innate repair receptor EPOR/βcR (CD131))

Key Features: A B-helix fragment derived from EPO that activates only the tissue repair pathway without stimulating erythropoiesis; it lacks EPO’s hematopoietic effects and does not increase the risk of thrombosis

Mechanism of Action (Research Focus)

1. Binds to the IRR receptor, activates the JAK2 / PI3K-Akt / STAT5 pathway, and inhibits apoptosis

2. Downregulates NF‑κB, exerts anti-inflammatory effects, and alleviates oxidative tissue damage

3. Research Focus: Small-fiber neuropathy, neuroprotection, diabetic neuropathy, renal ischemia-reperfusion injury, corneal nerve repair, and tissue repair following trauma or inflammation

Pharmacokinetic Properties

– Half-life: Approximately 2 min after intravenous administration; approximately 20 min after subcutaneous injection; rapid clearance (PMC)

– Appearance: White or off-white lyophilized powder; highly water-soluble

– Dissolution solvent: BAC water or AA sterile acetic acid solution (standard peptide resuspension system)

Storage Guidelines

– Lyophilized powder: Store long-term at -20°C; 2–8°C for short-term storage; protect from light and moisture

– After reconstitution: Refrigerate at 2–8°C for 2–4 weeks; aliquot and store at -20°C; repeated freeze-thaw cycles are strictly prohibited

Research Combination Recommendations

– Neuroinflammation / Neuropathic Pain: Often combined with BPC-157 to study tissue repair

– Metabolic neuropathy: May be used in combination with Semax and Selank for neuroprotection studies

⚠️ Important Notice

1. ARA‑290 (Cibinetide) is intended solely for in vitro and animal laboratory research; it is not approved for human clinical use, and injection into humans is strictly prohibited.

2. The information above is derived solely from peptide chemistry and pharmacology literature and does not constitute any medical advice.